De Laet C - Search Results

1

Cost-effectiveness of statins in the primary prevention of cardiovascular disease: a systematic review and economic analysis for Belgium.

Neyt M, De Laet C, Van Brabandt H, Franco O, Ramaekers D. Neyt M, et al. Among authors: de laet c. Acta Cardiol. 2009 Feb;64(1):1-10. doi: 10.2143/AC.64.1.2034354. Acta Cardiol. 2009. PMID: 19317290 Review.

2

Cost effectiveness of drug-eluting stents in Belgian practice: healthcare payer perspective.

Neyt M, De Laet C, De Ridder A, Van Brabandt H. Neyt M, et al. Among authors: de ridder a, de laet c. Pharmacoeconomics. 2009;27(4):313-27. doi: 10.2165/00019053-200927040-00004. Pharmacoeconomics. 2009. PMID: 19485427

3

Cost-effectiveness analyses of drug eluting stents versus bare metal stents: a systematic review of the literature.

Neyt M, Van Brabandt H, Devriese S, De Laet C. Neyt M, et al. Among authors: de laet c. Health Policy. 2009 Jul;91(2):107-20. doi: 10.1016/j.healthpol.2008.11.014. Epub 2009 Jan 9. Health Policy. 2009. PMID: 19135756 Review.

4

The polypill: at what price would it become cost effective?

Franco OH, Steyerberg EW, de Laet C. Franco OH, et al. Among authors: de laet c. J Epidemiol Community Health. 2006 Mar;60(3):213-7. doi: 10.1136/jech.2005.040253. J Epidemiol Community Health. 2006. PMID: 16476750 Free PMC article.

5

Primary prevention of cardiovascular disease: cost-effectiveness comparison.

Franco OH, der Kinderen AJ, De Laet C, Peeters A, Bonneux L. Franco OH, et al. Among authors: de laet c. Int J Technol Assess Health Care. 2007 Winter;23(1):71-9. doi: 10.1017/S0266462307051598. Int J Technol Assess Health Care. 2007. PMID: 17234019

6

Cost-effectiveness of human papillomavirus vaccination in Belgium: do not forget about cervical cancer screening.

Thiry N, De Laet C, Hulstaert F, Neyt M, Huybrechts M, Cleemput I. Thiry N, et al. Among authors: de laet c. Int J Technol Assess Health Care. 2009 Apr;25(2):161-70. doi: 10.1017/S0266462309090217. Int J Technol Assess Health Care. 2009. PMID: 19366497

7

Using threshold values for cost per quality-adjusted life-year gained in healthcare decisions.

Cleemput I, Neyt M, Thiry N, De Laet C, Leys M. Cleemput I, et al. Among authors: de laet c. Int J Technol Assess Health Care. 2011 Jan;27(1):71-6. doi: 10.1017/S0266462310001194. Epub 2011 Jan 25. Int J Technol Assess Health Care. 2011. PMID: 21262069 Review.

8

Cost-effectiveness of cardiac resynchronisation therapy for patients with moderate-to-severe heart failure: a lifetime Markov model.

Neyt M, Stroobandt S, Obyn C, Camberlin C, Devriese S, De Laet C, Van Brabandt H. Neyt M, et al. Among authors: de laet c. BMJ Open. 2011 Jan 1;1(2):e000276. doi: 10.1136/bmjopen-2011-000276. BMJ Open. 2011. PMID: 22021894 Free PMC article.

9

Calculating an intervention's (cost-)effectiveness for the real-world target population: the potential of combining strengths of both RCTs and observational data.

Neyt M, Cleemput I, Thiry N, De Laet C. Neyt M, et al. Among authors: de laet c. Health Policy. 2012 Jul;106(2):207-10. doi: 10.1016/j.healthpol.2012.04.014. Epub 2012 May 16. Health Policy. 2012. PMID: 22608108

10

The use of instrumental variables: an alternative to traditional modeling?

Neyt M, Van Brabandt H, De Laet C. Neyt M, et al. Among authors: de laet c. Value Health. 2011 Jan;14(1):1-2. doi: 10.1016/j.jval.2010.11.004. Value Health. 2011. PMID: 21211480 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

152 results

Search Page

Filters